Peanut oral immunotherapy is not ready for clinical use.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 20620564.
- Also identified by DOI 10.1016/j.jaci.2010.05.012 and PMC identifier 2904630.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Peanut OIT has shown promise as a potential treatment for food allergy. However, there remain numerous unanswered questions surrounding this investigational treatment, including the risks of OIT compared to avoidance, dosing regimen issues, patient selection, post-desensitization strategy, allocation of clinical resources, and reimbursement. Further studies are needed to address these outstanding issues in order to determine if this type of therapy is appropriate for clinical use.
Medical subject headings
- Desensitization, Immunologic
- Peanut Hypersensitivity